We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-9.15%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$44.2M
Cap. Flow
-$18.6M
Cap. Flow %
-17.11%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.8M
2
KURA icon
Kura Oncology
KURA
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.28B
$84.3M 77.49%
4,397,881
– –
KURA icon
2
Kura Oncology
KURA
$800M
$15M 13.83%
1,726,882
-123,065
-7% -$1.77M
LYEL icon
3
Lyell Immunopharma
LYEL
$317M
$5.33M 4.9%
416,250
– –
RLAY icon
4
Relay Therapeutics
RLAY
$4.1B
$4.12M 3.79%
1,000,000
– –
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-875,000
Closed -$16.8M

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q4 2024 Portfolio in Review

As of Q4 2024, Foresite Capital Management IV held 5 positions worth $109M, down 29% from $153M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV withdrew a net $18.6M in Q4 2024, closing 1 position and reducing 1 holding. Its most notable exit was Syndax Pharmaceuticals, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's biggest Q4 2024 reduction was Kura Oncology, cutting an estimated $1.77M.
  • Foresite Capital Management IV fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $16.8M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $109M portfolio in Q4 2024.
  • Foresite Capital Management IV opened 0 new positions and closed 1 in Q4 2024.
  • Foresite Capital Management IV's portfolio value fell 29% quarter-over-quarter to $109M.

Based on Foresite Capital Management IV's 13F filing for Q4 2024, filed 14 Feb 2025.